



TMH/YM4:lam 11/24/04 6395-64907-01

PATENT

1648

Chw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/701,536

Filed: June 18, 2001

Confirmation No. 5492

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1648

Attorney Reference No. 6395-64907-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed November 29, 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and enclosed herewith are three English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. This Supplemental Information Disclosure Statement ("IDS") is being mailed before Applicant received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c). Please charge any additional fees which may be required in connection with filing this Supplemental IDS, or credit any overpayment. Deposit Account Authority is given on the attached transmittal sheet.

12/03/2004 AADOF01 00000089 09701536

01 FC:1806


180.00 QP

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



TMH\K\H:lam 11/24/04 330337.doc I-008-97/1

PATENT
Attorney Reference Number 6395-64907-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/701,536

Filed: June 18, 2001

Confirmation No. 5492

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1648

Attorney Reference No. 6395-64907-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed November 29, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and three references cited thereon
- ☒ IDS Fee of \$180.00

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.


Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

By


Tanya M. Harding, Ph.D.
Registration No. 42,630

cc: Docketing



TMH/YSL:lam: 11/23/04 6395-64907-01 330335

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6395-64907-01
Application Number	09/701,536
Filing Date	June 18, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Chang <i>et al.</i> , "Recent advancement in flavivirus vaccine development," <i>Expert Rev. Vaccines</i> , 3(2):199-220 (2004).
		Guirakhoo <i>et al.</i> , "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates," <i>J. Virol.</i> , 74(12):5477-5485 (2000).
		Simmons <i>et al.</i> , "Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine," <i>Am. J. Trop. Med. Hyg.</i> 65(2):159-161 (2001).

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	